Board Changes – C4X Discovery appoints Simon Harford as Non-Executive Director

C4X Discovery Holdings plc

(“C4XD”, “C4X Discovery” or the “Company”)

Board Changes

C4X Discovery appoints Simon Harford as Non-Executive Director

GSK and Eli Lilly industry financial veteran further strengthens Board

20 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces the appointment of Simon Harford as Non-Executive Director with immediate effect.

Simon joins C4XD with more than 30 years of significant financial and investor relations expertise in global pharmaceutical companies.  Simon is currently CFO at Albireo Pharma Inc., a NASDAQ-listed biotech company where he has raised more than $200 million in equity financing and was previously CFO of Parexel International Inc., a global clinical research organisation, which was acquired by private equity in 2017.  Prior to this, Simon held various financial leadership roles at GSK, including SVP Finance, Global Pharmaceuticals.  During his tenure, he was responsible for finance in all pharmaceutical markets globally and was a member of the Global Pharmaceutical Operations Committee.  Simon also held key financial management roles at Eli Lilly and Company over two decades including Vice President and Controller, CFO and Executive Director Finance for Europe, Middle East and Africa (EMEA) and led the global investor relations function as Executive Director of Investor Relations.  He also received the Lilly, Chairman’s Ovation Award 2004 for outstanding achievement to Lilly.

Eva-Lotta Allan, Chairman of C4X Discovery, said:

“Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based.  His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior.  We welcome Simon to the Board and look forward to working closely with him.”

Simon Harford, incoming Non-Executive Director, added:

“I am delighted to be joining the C4XD Board at this stage of the Company’s development. C4XD has made great progress in the execution of its strategy, which the recent deal with Sanofi further validates. The Company’s technologies are able to deliver high quality and differentiated drug candidates for development by pharma and biotech companies and I look forward to working with the Board to continue growing the Company and delivering shareholder value.”

In accordance with Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies, additional information for Simon Nicolas Reade Harford, aged 60, is set out below:

Current Directorships                    Previous Directorships (last 5 years)
N/A Liquent, IncPAREXEL International Corporation

As of the date of this announcement, Simon Harford holds no ordinary shares in the capital of the Company.

There is no further information to disclose in respect of these appointments under Rule 17 and Schedule 2 paragraph (g) of the AIM Rules.

C4X Discovery Holdings plc

Mo Noonan, Communications+44 (0)7876 444 977

Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886 2500

Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

Consilium Strategic Communications

Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700

C4X Discovery (“C4XD”) is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for a commercial deal and to date we have successfully out-licensed two programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at or follow us on twitter @C4XDiscovery .

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).